Patents Assigned to Symphogen A/S
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230105714
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-NKG2A ANTIBODIES AND COMPOSITIONS
    Publication number: 20220389100
    Abstract: This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: May 31, 2022
    Publication date: December 8, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Randi Westh Hansen, Franziska Katharina Uhlenbrock, Nikolaj Dietrich, Anne Worsaae, Michael Monrad Grandal
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20220380470
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: June 7, 2022
    Publication date: December 1, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220363757
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: November 17, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-LAG-3 antibodies and compositions
    Patent number: 11390676
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-TIM-3 antibodies and compositions
    Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-PD-1 antibodies and compositions
    Patent number: 11359018
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 14, 2022
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Thomas Bouquin, Klaus Koefoed, Torben Gjetting, Vikram Kjoller Bhatia, Monika Gad, Gunther Roland Galler, Camilla Frohlich
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220056126
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 24, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210317216
    Abstract: This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 14, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Maria Carlsen Melander, Matteo Riva, Mikkel Wandahl Pedersen, Randi Westh HANSEN
  • ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210284734
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Anti-AXL Antibodies and Compositions
    Publication number: 20210269532
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Torben GJETTING, Trine LINDSTED, Anton WILLER, Anne WORSAAE, Maria Carlsen MELANDER, Janus Schou JAKOBSEN, Randi Westh HANSEN
  • ANTI-CD40 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210214454
    Abstract: This invention relates to anti-CD40 antibodies and methods of using them in treating diseases and conditions related to CD40 activity, e.g., cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 15, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Anton WILLER, Trine LINDSTED, Klaus KOEFOED, Mikkel Wandahl PEDERSEN, Lise Camilla FRÖHLICH
  • Anti-PD-1 antibodies and compositions
    Patent number: 11034765
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 15, 2021
    Assignee: Symphogen A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • ANTI-CD73 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210070876
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20200407444
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 31, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-EGFR ANTIBODIES
    Publication number: 20200347140
    Abstract: The present invention provides methods and uses of anti-EGFR antibody compositions for treatment of cancers that are negative for certain mutations in RAS, BRAF, and the EGFR extracellular domain and are resistant to other anti-EGFR therapies.
    Type: Application
    Filed: August 29, 2018
    Publication date: November 5, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Kragh, Thomas Tuxen POULSEN, Cliff DING, Ivan David Horak
  • Anti-PD-1 Antibodies and Compositions
    Publication number: 20190367616
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Johan LANTTO, Thomas BOUQUIN, Klaus KOEFOED, Torben GJETTING, Vikram Kjoller BHATIA, Monika GAD, Gunther Roland GALLER, Camilla FROHLICH
  • Anti-MET antibodies and compositions
    Patent number: 10450376
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 22, 2019
    Assignee: Symphogen A/S
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190144542
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 16, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen